Contact
Please use this form to send email to PR contact of this press release:
Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis
TO:
Please use this form to send email to PR contact of this press release:
Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis
TO: